Evaluating circulating tumor DNA from the cerebrospinal fluid of patients with melanoma and leptomeningeal disease

Research output: Contribution to journalArticlepeer-review

56 Scopus citations

Abstract

Circulating tumor DNA (ctDNA) refers to tumor-derived cell-free DNA that circulates in body fluids. Fluid samples are easier to collect than tumor tissue, and are amenable to serial collection at multiple time points during the course of a patient's illness. Studies have demonstrated the feasibility of performing mutation profiling from blood samples in cancer patients. However, detection of ctDNA in the blood of patients with brain tumors is suboptimal. Cerebrospinal fluid (CSF) can be obtained via lumbar puncture or intraventricular catheter, and may be a suitable fluid to assess ctDNA in patients with brain tumors. We detected melanoma-associated mutations by droplet-digital PCR (ddPCR) and next-generation sequencing in ctDNA obtained from the CSF (CSF-ctDNA) of melanoma patients with leptomeningeal disease. There is a strong correlation between mutation detection by ddPCR, the presence of circulating tumor cells in CSF and abnormalities in the MRI. However, approximately 30% of CSF samples that were negative or indeterminate for the presence of tumor cells by microscopic examination were positive for CSF-ctDNA by ddPCR. Our results demonstrate that CSF is a suitable fluid for evaluating ctDNA and ddPCR is superior to CSF-cytology for analysis of CSF in melanoma patients with leptomeningeal disease.

Original languageEnglish (US)
Pages (from-to)628-635
Number of pages8
JournalJournal of neuropathology and experimental neurology
Volume77
Issue number7
DOIs
StatePublished - Jul 1 2018

Keywords

  • Cerebrospinal fluid
  • Circulating tumor DNA
  • Leptomeningeal disease
  • Liquid biopsy
  • Melanoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'Evaluating circulating tumor DNA from the cerebrospinal fluid of patients with melanoma and leptomeningeal disease'. Together they form a unique fingerprint.

Cite this